MSC III Problems and Solutions in MSCs to the Clinic

MSC III Problems and Solutions in the Translation of MSCs to Clinical Practice

Introduction

  • Presenter: S.M. Cool
  • Position: Professor of Bioengineering at the University of Queensland.
  • Date of presentation: February 9, 2009 to August 7, 2006.

Australia’s Aging Population

  • Statistic: By 2057, approximately 22% of Australia’s population will be aged 65 years or older (source: Insight Study, CSU).

Advances in Regenerative Medicine

  • Focus on regenerative medicine which includes cellular therapies and gene editing as curative treatments.
  • Current treatments focus on symptomatic relief using drugs and surgical interventions.
  • The global economic burden of aging populations is significant.

Disease Expenditure in Australia

  • Reference to the Australian Burden of Disease expenditure data from 2018-19, highlighting the financial impacts on the health system.

Definition of Health

  • Definition outlined by Nature (March 2018): Health can be defined by one’s ability to take care of oneself.

Available MSCs for Tissue Repair

  • Important passage from Caplan (2009) regarding the decreasing availability of mesenchymal stem cells (MSCs) as we age, impacting tissue repair and regeneration.
  • Notable visualization of MSC population dynamics with age.

Bottlenecks in MSC Manufacturing

  • Recognition that there are significant bottlenecks in MSC manufacturing affecting their clinical potential and applicability in therapies.

Centenarian Prevalence by Country

  • Current data on centenarians around the world, identifying prevalence in various countries, with projections for 2050.

Global Pipeline of MSC Products

  • Breakdown of clinical trial phases (Phase I to Phase IV) and types of MSC products (autologous vs allogeneic).
  • Total of 1025 clinical trials recorded; 63% in preliminary phases.

Approved Regenerative Medicines in Australia

  • Overview of several therapies including:
    • Spinraza (nusinersen) - Gene Therapy for Spinal Muscular Atrophy.
    • Kymriah (tisagenlecleucel) - Cell Therapy for various cancers.
  • These therapies illustrate current advancements and regulatory approvals in regenerative medicine.

Clinical Trials in Regenerative Medicine

  • A noted increase in clinical trials from March 2015 to March 2021 in Australia focusing more on gene therapy and cell-based therapies.

Trends in Regenerative Therapies

  • Most new clinical trials in Australia primarily focus on allogeneic therapies using MSCs sponsored by industry.

Development Pathways

  • Depiction of the development pathway for bio-pharmaceuticals vs. medical devices, showing the timelines for clinical trials, regulatory approvals, and market launch.

Linking Mechanism of Action to Clinical Outcomes

  • Discussion on the importance of linking the mechanism of action to positive clinical outcomes, citing an example of Mesoblast’s challenges with the FDA concerning their MSC therapy for GVHD.

Factors Affecting MSC Variation and Efficacy

  • Variability in MSC preparation, isolation, and administration methods contributes significantly to clinical efficacy.
  • Detailed factors include donor health status, method of isolation, media, and environmental conditions during MSC growth.

Strategies for Donor Selection

  • Insights on current vs proposed donor selection methods, emphasizing the need for quality assessments based on biomarkers rather than just age and health status.

Challenges in Banking Potent MSCs

  • Discusses the challenges in banking highly potent MSCs, with emphasis on donor quality variability and potential solutions for standardization and efficiency.

Growth Characteristics of MSCs

  • The relationship between donor age and MSC growth capabilities, citing specific markers and conditions impacting growth rates (e.g., FGF2 expression).

Need for Improved Manufacturing Processes

  • Recognition of the practicality of manufacturing high quantities of viable MSCs for therapeutic use. Current manufacturing methods yield insufficient numbers.

MSC Priming and Engineering Strategies

  • Discusses potential methods for enhancing MSC therapeutic outcomes, including priming with growth factors or vitamins, and engineering more robust cell types.

Solutions for Aging and Cellular Repair

  • The presentation discusses the importance of interventions targeting heparan sulfate interactions with growth factors to enhance cellular proliferation and responses in MSC treatments.

Conclusion

  • Highlighting ongoing research and development aimed at enhancing the efficacy and quantity of MSCs for future clinical applications, with attention to precision medicine strategies.